Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

The cost-effectiveness and budget impact of stepwise addition of bolus insulin in the treatment of type 2 diabetes: evaluation of the FullSTEP trial.

Saunders R, Lian J, Karolicki B, Valentine W.

J Med Econ. 2014 Dec;17(12):827-36. doi: 10.3111/13696998.2014.959590. Epub 2014 Sep 12.

PMID:
25168164
2.

Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial.

Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH.

Lancet Diabetes Endocrinol. 2014 Jan;2(1):30-7. doi: 10.1016/S2213-8587(13)70090-1. Epub 2013 Sep 25. Erratum in: Lancet Diabetes Endocrinol. 2014 Jan;2(1):e3.

PMID:
24622667
3.

Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway.

Huetson P, Palmer JL, Levorsen A, Fournier M, Germe M, McLeod E.

J Med Econ. 2015;18(8):573-85. doi: 10.3111/13696998.2015.1038271. Epub 2015 Jun 1.

PMID:
25853868
5.

Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.

Testa MA, Gill J, Su M, Turner RR, Blonde L, Simonson DC.

J Clin Endocrinol Metab. 2012 Oct;97(10):3504-14. doi: 10.1210/jc.2012-1763. Epub 2012 Jul 31.

PMID:
22851487
6.

Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK.

Valentine WJ, Curtis BH, Pollock RF, Van Brunt K, Paczkowski R, Brändle M, Boye KS, Kendall DM.

Diabetes Res Clin Pract. 2015 Jul;109(1):95-103. doi: 10.1016/j.diabres.2015.04.023. Epub 2015 Apr 21.

PMID:
25989713
7.

Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.

Ericsson Å, Pollock RF, Hunt B, Valentine WJ.

J Med Econ. 2013 Dec;16(12):1442-52. doi: 10.3111/13696998.2013.852099. Epub 2013 Oct 25.

PMID:
24147661
10.

Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.

Ray JA, Valentine WJ, Roze S, Nicklasson L, Cobden D, Raskin P, Garber A, Palmer AJ.

Diabetes Obes Metab. 2007 Jan;9(1):103-13.

PMID:
17199725
11.

Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.

Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, Palmer AJ, Roze S.

Curr Med Res Opin. 2008 May;24(5):1417-28. doi: 10.1185/030079908X297295 . Epub 2008 Apr 8.

PMID:
18400145
12.

Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.

Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ.

Int J Clin Pharmacol Ther. 2009 Aug;47(8):501-15.

PMID:
19640359
13.

Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.

Tunis SL, Minshall ME, Conner C, McCormick JI, Kapor J, Yale JF, Groleau D.

Curr Med Res Opin. 2009 May;25(5):1273-84. doi: 10.1185/03007990902869169 .

PMID:
19366302
14.

Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design.

Levin PA, Zhang Q, Mersey JH, Lee FY, Bromberger LA, Bhushan M, Bhushan R.

Clin Ther. 2011 Jul;33(7):841-50. doi: 10.1016/j.clinthera.2011.05.091. Epub 2011 Jun 30.

PMID:
21719107
15.

Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study.

Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, Araki E, Shichiri M.

Diabetes Res Clin Pract. 2000 Jun;48(3):201-10.

PMID:
10802159
16.

Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.

Tunis SL, Sauriol L, Minshall ME.

Appl Health Econ Health Policy. 2010;8(4):267-80. doi: 10.2165/11535380-000000000-00000.

PMID:
20578781
17.

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.

Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:43-55. doi: 10.1111/j.1463-1326.2008.00886.x.

PMID:
18435673
18.

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.

Warren E, Weatherley-Jones E, Chilcott J, Beverley C.

Health Technol Assess. 2004 Nov;8(45):iii, 1-57. Review.

19.

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany.

Pscherer S, Dietrich ES, Dippel FW, Neilson AR.

Ger Med Sci. 2010 Aug 5;8. pii: Doc17. doi: 10.3205/000106.

20.

Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.

Valentine WJ, Erny-Albrecht KM, Ray JA, Roze S, Cobden D, Palmer AJ.

Adv Ther. 2007 Mar-Apr;24(2):273-90.

PMID:
17565917

Supplemental Content

Support Center